Nothing Special   »   [go: up one dir, main page]

RS20050690A - 2-(butyl-1-sulfonylamino)-n-/1(r)-(6- methoxy-pyridin-3-yl)-propyl/- benzamid, the use thereof in form of drug an pharmaceutical preparation contain ing said compound - Google Patents

2-(butyl-1-sulfonylamino)-n-/1(r)-(6- methoxy-pyridin-3-yl)-propyl/- benzamid, the use thereof in form of drug an pharmaceutical preparation contain ing said compound

Info

Publication number
RS20050690A
RS20050690A YUP-2005/0690A YUP20050690A RS20050690A RS 20050690 A RS20050690 A RS 20050690A YU P20050690 A YUP20050690 A YU P20050690A RS 20050690 A RS20050690 A RS 20050690A
Authority
RS
Serbia
Prior art keywords
benzamid
sulfonylamino
pyridin
methoxy
propyl
Prior art date
Application number
YUP-2005/0690A
Other languages
Serbian (sr)
Inventor
Klaus Wirth
Joachim BRENDEL
Heinz Goegelein
Gert Ulrich Kuerzel
Original Assignee
Sanofi-Aventis Deutschland Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh., filed Critical Sanofi-Aventis Deutschland Gmbh.,
Publication of RS20050690A publication Critical patent/RS20050690A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention relates to 2-(Butyl-1-sulfonylamino)-N-[1 (R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid of formula (I), and to the pharmaceutically acceptable salts thereof. Said invention also relates to the production and use of the inventive compound or the pharmaceutically acceptable salts thereof, in particular for treating and preventing auricular arrhythmia, for example auricular fibrillation (atrial fibrillation) or auricular flutter (atrial flutter).
YUP-2005/0690A 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-/1(r)-(6- methoxy-pyridin-3-yl)-propyl/- benzamid, the use thereof in form of drug an pharmaceutical preparation contain ing said compound RS20050690A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (en) 2003-03-18 2003-03-18 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3yl) -propyl] -benzamide, its use as a medicament and pharmaceutical compositions containing the same
PCT/EP2004/002247 WO2004083157A1 (en) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound

Publications (1)

Publication Number Publication Date
RS20050690A true RS20050690A (en) 2008-04-04

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0690A RS20050690A (en) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-/1(r)-(6- methoxy-pyridin-3-yl)-propyl/- benzamid, the use thereof in form of drug an pharmaceutical preparation contain ing said compound

Country Status (22)

Country Link
EP (1) EP1606237A1 (en)
JP (1) JP2006520343A (en)
KR (1) KR20050110681A (en)
CN (1) CN100361943C (en)
AR (1) AR043622A1 (en)
AU (1) AU2004222137A1 (en)
BR (1) BRPI0408441A (en)
CA (1) CA2519022A1 (en)
DE (1) DE10312073A1 (en)
HK (1) HK1086819A1 (en)
HR (1) HRP20050815A2 (en)
MA (1) MA27749A1 (en)
MX (1) MXPA05009763A (en)
MY (1) MY176510A (en)
NO (1) NO20054472L (en)
NZ (1) NZ542476A (en)
PE (1) PE20050307A1 (en)
RS (1) RS20050690A (en)
RU (1) RU2333202C2 (en)
TW (1) TW200500342A (en)
WO (1) WO2004083157A1 (en)
ZA (1) ZA200506328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (en) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (en) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
EP1909572A4 (en) * 2005-07-22 2010-09-08 Merck Sharp & Dohme Potassium channel inhibitors
WO2010137351A1 (en) 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121003A1 (en) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
KR20050110681A (en) 2005-11-23
CA2519022A1 (en) 2004-09-30
NO20054472L (en) 2005-09-27
NZ542476A (en) 2008-05-30
BRPI0408441A (en) 2006-04-04
MY176510A (en) 2020-08-12
HRP20050815A2 (en) 2006-09-30
WO2004083157A1 (en) 2004-09-30
DE10312073A1 (en) 2004-09-30
JP2006520343A (en) 2006-09-07
ZA200506328B (en) 2006-04-26
MXPA05009763A (en) 2006-01-27
MA27749A1 (en) 2006-02-01
PE20050307A1 (en) 2005-06-08
AU2004222137A1 (en) 2004-09-30
EP1606237A1 (en) 2005-12-21
CN100361943C (en) 2008-01-16
RU2005132163A (en) 2006-04-10
TW200500342A (en) 2005-01-01
RU2333202C2 (en) 2008-09-10
CN1756728A (en) 2006-04-05
AR043622A1 (en) 2005-08-03
HK1086819A1 (en) 2006-09-29

Similar Documents

Publication Publication Date Title
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
RS82003A (en) Anthranilic acid amides, method for the production thereof, their use as antiarhythmia agents, and pharmaceutical preparations thereof
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
BR0313176A (en) Pyrazole compositions useful as gsk-3 inhibitors
BRPI0307351B8 (en) compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
WO2001019776A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
BR0014178A (en) Dicarboxylic acid derivatives with pharmaceutical properties
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
RU95101048A (en) Prolineamide derivatives and pharmcomposition based thereon
UA94901C2 (en) Antibacterial piperidine derivatives
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TR200200883T2 (en) 2-substituted 1,1-biphenyl-2-carbonamides, manufacturing methods, use as drugs
EP1201239A4 (en) Cyclic amine ccr3 antagonists
BR0210028A (en) Antibacterial agents
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
SE9900961D0 (en) Novel compounds
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
PT992509E (en) NEW MACROLIDED DERIVATIVES
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders